ANTI-VIRAL PYRIMIDINE DERIVATIVES
Compounds and compositions which are useful for the treatment of viral infections, particularly human Cytomegalovirus infection. The compounds include novel pyrimidine-based derivatives having formula (I) wherein X is a member selected from the group consisting of -NR R , -OR , -SR , aryl, alkyl and...
Gespeichert in:
Hauptverfasser: | , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; fre |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Compounds and compositions which are useful for the treatment of viral infections, particularly human Cytomegalovirus infection. The compounds include novel pyrimidine-based derivatives having formula (I) wherein X is a member selected from the group consisting of -NR R , -OR , -SR , aryl, alkyl and arylalkyl; Y is a member selected from the group consisting of a covalent bond, -N(R )-, -O-, -S-, -C(=O)- and alkylene; R and R are members independently selected from the group consisting of hydrogen, alkyl, -O-alkyl, -S-alkyl, aryl, arylalkyl, -O-aryl, -S-aryl, -NO2, -NR R , -C(O)R , -CO2R , -C(O)NR R , -N(R )C(O)R , -N(R )CO2R , -N(R )C(O)NR R , -S(O)mNR R , -S(O)nR , -CN, halogen, and -N(R )S(O)mR .
L'invention concerne des composés et des compositions convenant au traitement d'infections virales, et en particulier, chez l'homme, l'infection par Cytomégalovirus. Ces composés contiennent les dérivés à base de pyrimidine de l'invention, représentés par la formule générale (I). Dans cette formule, X appartient au groupe des -NR R , -OR , -SR , aryle, alkyle et arylalkyle; Y appartient au group constitué d'une liaison covalente, des -N(R )-, -O-, -S-, -C(=O)-, et de l'alkylène; R et R appartiennent chacun indépendamment au groupe des hydrogène, alkyle, -O-alkyle, -S-alkyle, aryle, arylalkyle, -O-aryle, -S-aryle, -NO2, -NR R , -C(O)R , -CO2R , -C(O)NR R , -N(R )C(O)R , -N(R )CO2R , -N(R )C(O)NR R , -S(O)mNR R , -S(O)nR , -CN, halogène, et -N(R )S(O)mR . |
---|